References in periodicals archive ?
Sales of the twice-daily injectable diabetes treatment Byetta fell 20% to $140.7 million while sales of diabetes medication Symlin accounted for $21.8 million in revenue.
Pramlintide (Symlin), a daily injectable, decreases the speed at which sugar enters the blood after a meal by slowing digestion.
In March 2005, for example, the RiskMAP that accompanied the FDA's approval of a diabetes drug called Symlin prohibited the company from conducting any direct-to-consumer advertising or journal advertising for one year following approval, and also restricted promotion primarily to physicians who specialize in diabetes management and who are supported by certified diabetes educators.
The morning after the company's diabetes drug, Symlin, was finally approved by the federal government after 18 years of research and development, she arrived in the office in a Sleeping Beauty costume and handed out copies of the fairy tale.
In July 2012, BMS and AZ worked together to acquire Amylin and its injectable diabetes treatments, Byetta, By-dureon and Symlin, for $5.3 billion.
This agreement will see the company sell its global diabetes business that was part of its collaboration with AstraZeneca, which includes Onglyza (saxagliptin), Kombiglyze XR/Komboglyze (saxagliptin and metformin HCl extended release), dapagliflozin (marketed as Forxiga outside the US), Byetta (exenatide), Bydureon (exenatide extended release for injectable suspension), Symlin (pramlintide acetate) and metreleptin.
Upon completion of the transaction, AstraZeneca will own intellectual property and global rights for the development, manufacture and commercialisation of the diabetes business, which includes Onglyza (saxagliptin), Kombiglyze XR (saxagliptin and metformin HCl extended release), Komboglyze (saxagliptin and metformin HCl), dapagliflozin (marketed as Forxiga outside the US), Byetta (exenatide), Bydureon (exenatide extended-release for injectable suspension), metreleptin and Symlin (pramlintide acetate).
Sales of Byetta edged higher and Symlin revenue slipped, but a change in accounting cut its revenue by $27.7 million.
Some drugs in these classes already have been approved, most notably the incretin mimetic exenatide (Byetta), an inhaled insulin (Exubera), and the amylin analogue pramlintide (Symlin).
Most recently the agency approved Amylin Pharmaceuticals' injectable diabetes drug Symlin on the condition that it not be advertised directly to consumers or in medical journals for a year.
21 June 2011 - US-based biopharmaceutical company Amylin Pharmaceuticals Inc (NASDAQ: AMLN) said yesterday that it will present data for its two first-in-class diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, 24-28 June.
Pramlintide (Symlin) is an injectable synthetic analogue of human amylin, a peptide hormone that is naturally cosecreted with insulin in response to meals.